Literature DB >> 3197821

Bone marrow karyotype and prognosis in primary myelodysplastic syndromes.

R Billström1, T Thiede, S Hansen, S Heim, U Kristoffersson, N Mandahl, F Mitelman.   

Abstract

Bone marrow karyotype, survival time, and the rate of progression to leukaemia were studied in 111 unselected patients with primary myelodysplastic syndromes. The 49 patients (44%) with clonal chromosome aberrations had survival time (median 29 months) similar to that found in the 62 patients with normal bone marrow karyotype (24 months, p greater than 0.10). The presence of multiple (greater than 2) abnormalities (17 patients) was strongly associated with poor prognosis, with a median survival of only 7 months (p less than 0.001). Prognostic information could be attributed to 2 specific abnormalities, del(5q) and -7: Presence of del(5q) as the sole anomaly was associated with long survival (36+ months), whereas monosomy 7 was a bad prognostic sign (6 months). The risk for leukaemia development correlated neither with the number of chromosome abnormalities nor with any particular anomaly. Our findings demonstrate the prognostic importance of quantifying the complexity of bone marrow chromosome changes. They also emphasize that different specific abnormalities convey widely different prognostic information in primary myelodysplastic syndromes.

Entities:  

Mesh:

Year:  1988        PMID: 3197821     DOI: 10.1111/j.1600-0609.1988.tb00207.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  8 in total

1.  The impact of category, cytopathology and cytogenetics on development and progression of clonal and malignant myeloid transformation in inherited bone marrow failure syndromes.

Authors:  Michaela Cada; Catherin I Segbefia; Robert Klaassen; Conrad V Fernandez; Rochelle A Yanofsky; John Wu; Yves Pastore; Mariana Silva; Jeffrey H Lipton; Josee Brossard; Bruno Michon; Sharon Abish; MacGregor Steele; Roona Sinha; Mark Belletrutti; Vicky Breakey; Lawrence Jardine; Lisa Goodyear; Lillian Sung; Mary Shago; Joseph Beyene; Preeti Sharma; Bozana Zlateska; Yigal Dror
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

2.  Chromosome analyses in patients with myelodysplastic syndromes: correlation with bone marrow histopathology and prognostic significance.

Authors:  M Werner; H Maschek; V Kaloutsi; H Choritz; A Georgii
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

3.  Correlations between cytogenetics and morphology in myelodysplastic syndromes.

Authors:  L Vila; C Charrin; E Archimbaud; D Treille-Ritouet; J Fraisse; P Felman; D Fiere; D Germain
Journal:  Blut       Date:  1990-04

4.  Ring chromosome 8 and trisomy 8 in a patient with acute myeloid leukemia.

Authors:  Bibhas Kar; B Nandhini; R Revathi
Journal:  Indian J Hematol Blood Transfus       Date:  2009-04-06       Impact factor: 0.900

5.  Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

Authors:  Ying Jiang; Andrew Dunbar; Lukasz P Gondek; Sanjay Mohan; Manjot Rataul; Christine O'Keefe; Mikkael Sekeres; Yogen Saunthararajah; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2008-10-02       Impact factor: 22.113

Review 6.  FAB classification of myelodysplastic syndromes: merits and controversies.

Authors:  G E Verhoef; S Pittaluga; C De Wolf-Peeters; M A Boogaerts
Journal:  Ann Hematol       Date:  1995-07       Impact factor: 3.673

7.  Cytogenetic findings in 179 patients with myelodysplastic syndromes.

Authors:  D Haase; C Fonatsch; M Freund; B Wörmann; H Bodenstein; H Bartels; B Stollmann-Gibbels; E Lengfelder
Journal:  Ann Hematol       Date:  1995-04       Impact factor: 3.673

Review 8.  Cytogenetic features in myelodysplastic syndromes.

Authors:  Detlef Haase
Journal:  Ann Hematol       Date:  2008-04-15       Impact factor: 3.673

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.